Mass spectrometric characterization of urinary hydrafinil metabolites for routine doping control purposes

Little information on the human metabolism and urinary elimination of hydrafinil (9-fluorenol) exists. In order to support preventive anti-doping activities concerning compounds such as hydrafinil, a pilot elimination study was conducted with three healthy male volunteers receiving a single oral dose of 50 mg of hydrafinil. Urine samples were collected prior to and up to 72-h post-administration and were subjected to both gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry, which allowed for the identification of the intact drug as well as Phase I and Phase II metabolites, primarily hydroxylated and/or glucuronidated or sulfo-conjugated hydrafinil. The identity of these metabolites was corroborated by high-resolution/high-accuracy tandem mass spectrometry, and the applicability of routine doping control workflows for the detection of hydrafinil and its main metabolites was assessed. Therefore, two findings of hydrafinil and its metabolites were recorded, which concerned out-of-competition doping control samples and, hence, were not pursued with confirmatory analyses. Yet, the initial testing procedure results indicate that hydrafinil might require consideration in sports drug testing programs to ensure its detection, if classified as prohibited by the World Anti-Doping Agency (WADA).

Automated summary

A pilot elimination study was conducted with three healthy male volunteers who received a single oral dose of 50 mg of hydrafinil to investigate its metabolism and urinary elimination. The study identified Phase I and Phase II metabolites of hydrafinil through gas and liquid chromatography-mass spectrometry and assessed the applicability of routine doping control workflows for detection. The results suggest that hydrafinil may need to be considered in sports drug testing programs to ensure detection if classified as prohibited by WADA.